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Background: Progression of non-small cell lung cancer (NSCLC)
from early- to late-stage may signify the accumulation of gene
mutations. An advanced-stage tumor’s mutation profile may also
have prognostic value, guiding treatment decisions. Mutation detec-
tion of multiple genes is limited by the low amount of deoxyribo-
nucleic acid extracted from low-volume diagnostic lung biopsies.
We explored whole genome amplification (WGA) to enable multiple
molecular analyses.
Methods: Eighty-eight advanced-stage NSCLC patients were en-
rolled. Their low-volume lung biopsies underwent WGA before
direct sequencing for epidermal growth factor receptor (EGFR),
KRAS (rat sarcoma virus), p53, and CMET (mesenchymal-epithelial
transition factor) mutations. Overall survival impact was examined.
Surgically-resected tumors from 133 early-stage NSCLC patients
were sequenced for EGFR, KRAS and p53 mutations. We compared
the mutation frequencies of both groups.
Results: It is feasible for low-volume lung biopsies to undergo
WGA for mutational analysis. KRAS and CMET mutations have a
deleterious effect on overall survival, hazard ratios 5.05 (p  0.009)
and 23.65 (p  0.005), respectively. EGFR and p53 mutations,
however, do not have a survival impact. There also does not seem to
be significant differences in the frequency of mutations in EGFR,
KRAS, and p53 between early- and advanced-stage disease: 20%
versus 24% (p 0.48), 29% versus 27% (p 0.75), 10% versus 6%
(p  0.27), respectively.
Conclusions: In advanced-stage NSCLC, KRAS, and CMET muta-
tions suggest poor prognosis, whereas EGFR and p53 mutations do
not seem to have survival impact. Mutations in EGFR, KRAS and
p53 are unlikely to be responsible for the progression of NSCLC
from early- to late-stage disease. WGA may be used to expand
starting deoxyribonucleic acid from low-volume lung biopsies for
further analysis of advanced-stage NSCLC.
Key Words: Non-small cell lung cancer, Advanced stage, Early
stage, Whole genome amplification, Low-volume biopsies, KRAS
mutations, CMET mutations, EGFR mutations, p53 mutations,
Prognosis.
(J Thorac Oncol. 2009;4: 12–21)
Lung cancer remains the leading cause of cancer mortality,comprising 17.6% of cancer deaths worldwide, with an
average 5-year survival of 9 to 15%.1 Non-small cell lung
cancer (NSCLC) is more common (85% versus 15% being
small cell lung cancer), and is the focus of this report.
The poor survival statistics can be largely attributed to
the advanced stage of disease at presentation in the majority
of NSCLC cases. Currently, the tumor, node, metastasis
(TNM) stage at presentation still has the greatest impact on
prognosis, as shown by the 5-year survival data collected for
the proposed 7th TNM staging system2: for pathologic stage
I, II, III, and IV, they were 58 to 73%, 36 to 46%, 9 to 24%,
and 13%, respectively; for clinical stage I, II, III, and IV, they
were 43 to 50%, 25 to 36%, 7 to 19%, and 2%, respectively.
To improve overall clinical outcomes requires consid-
eration of several factors, including effective measures for
early disease detection (not dealt with here), as well as
elucidating molecular processes underlying carcinogenesis
and disease progression. Expanding on the concept that a
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tumor cell acquires and accumulates molecular events that
increasingly affect its invasive and metastatic nature, it is not
unreasonable to envisage this evolution in cell behavior to
coincide with the clinically manifested disease stage. There-
fore, we may expect molecular profiles that distinguish early-
from late-stage disease. Identifying these differences may
lead to the devising of measures to arrest these changes.
The systematic evaluation of advanced-stage NSCLC
tumors, however, has been hampered by the relative lack of
tissue for molecular analysis. A lot of the data on NSCLC
molecular genetics has been garnered from early-stage dis-
ease, where there is ample tissue from surgical resections, but
which only comprise the minority of cases (20–30%). For
advanced-stage NSCLC, available tissue is usually restricted
to the low-volume biopsies obtained during the diagnostic
procedure. The low abundance of tissue precludes guarantee-
ing sufficient cells leftover for paraffin-embedment and subse-
quent molecular analysis for every single case. In Shih et al.’s3
retrospective study of lung cancer patients on gefitinib treat-
ment, 75 of 139 (54%) patients did not have paraffin-embed-
ded cells from their diagnostic biopsies for deoxyribonucleic
acid (DNA) sequencing and were therefore excluded from
analysis. In the TRIBUTE trial,4 of the 710 patients who gave
consent to releasing their archival tumor samples for re-
search, 479 (67%) had samples available, of which 274 (39%)
contained enough tumor cells to attempt DNA sequencing.
This dropout rate needs to be reduced, especially in the
context of developing personalized medicine, where the in-
tention is to use the molecular data from the individual’s
malignant tissue to guide ensuing treatment. We previously
proposed an alternative strategy of obtaining separate biop-
sies during the diagnostic procedure and tested its feasibility
in the clinical context.5–7
Here, we hypothesize that a profile of a tumor’s gene
mutations can prognosticate and guide treatment decisions in
advanced NSCLC cases, e.g., whether to initiate treatment in
the context of borderline performance status. Additionally, if
drugs are developed that tend to induce tumor response in the
context of particular gene mutations, e.g., tyrosine kinase
inhibitors (TKI) and epidermal growth factor receptor
(EGFR) mutations,8–10 then knowing the mutation profile of
the tumor would be a prerequisite. Hence, developing a
system that achieves this from low-volume lung biopsies is
clinically relevant.
We had previously explored and tested various ways to
maximize the yield of molecular data from these low-volume
biopsies, as a means to gaining insight on advanced-stage
NSCLC.5–7 We attempted to define the limits of mutational
analysis of these samples through direct sequencing.6 We
decided to test whole-genome amplification (WGA) as a
means of pushing these technical boundaries. Ideally, WGA
amplifies DNA to sufficient levels for reliable laboratory
analysis, and still retains an accurate representation of the
original sample. Several methods exist to enhance the repli-
cation fidelity.11–13 We used the multiple displacement am-
plification method in this study, which had previously been
tested on clinical samples.14
Apart from testing the feasibility of gene mutation
detection in WGA-amplified genomic DNA from low-
volume lung biopsies, we wanted to evaluate the mutation
status of EGFR, KRAS (rat sarcoma virus), p53, and CMET
(mesenchymal-epithelial transition factor) in advanced-stage
NSCLC and their relation to overall survival. This assesses
the suitability of their being included in a panel of mutations
of putative clinical significance, as mentioned earlier.
Here, we report the feasibility of using WGA on low-
volume lung biopsies for increasing the potential yield of
mutation data, the survival analysis of 88 patients with
corresponding mutational status obtained via direct sequenc-
ing of WGA-amplified genomic DNA from low-volume lung
biopsies, and a comparison of mutation frequencies between
early- and advanced-stage disease.
METHODS
Patients and Sample Collection
Approvals for this study were obtained from the Insti-
tutional Review Boards of the National University Hospital,
Tan Tock Seng Hospital and National Cancer Centre, Singa-
pore. Samples were obtained from patients with informed
consent. For patients undergoing surgery, tumor tissue
(1 cm3) was obtained from each patient ex vivo. For patients
undergoing nonsurgical diagnostic procedures, study samples
were obtained if the preceding sample was assessed by a
cytologist to contain sufficient cells for diagnosis. Therefore,
study samples were acquired in the same sitting as the
diagnostic procedure, but were separate from the diagnostic
biopsies, thereby not compromising the usual diagnostic
process. Bronchoscopic biopsies were obtained with a 22-
gauge Wang cytology needle (Bard Endoscopic Technolo-
gies, Billerica, MA) or forceps (Olympus America Inc.,
Center Valley, PA). Percutaneous needle aspirates were ob-
tained with computed tomography/fluoroscopic guidance us-
ing an 18- or 20-gauge Quick-Core needle (Cook Inc.,
Bloomington, IN), or 20-gauge Chiba or Westcott needles
(Medical Device Technologies Inc., Gainesville, FL). As
these were diagnostic procedures, a range of pathologies was
included. NSCLCs of various histologic subtypes were cov-
ered, including adenocarcinoma, squamous cell carcinoma,
and large cell carcinoma. Each aspirate and surgical sample
was collected in 80 l and 1 ml of ribonucleic acid (RNA)
later (Ambion, Austin, TX), respectively.
Preparation of Genomic DNA
Genomic DNA was extracted from fresh surgical tis-
sues with Puregene DNA purification kits (Gentra Systems
Inc., Minneapolis, MN), using isopropanol for DNA precip-
itation. To maximize yield for the low-volume samples, DNA
precipitation was achieved with oyster glycogen (Sigma-
Aldrich, St. Louis, MO) added to the last step to a final
concentration of 0.02 g/l, then overnight incubation at
20°C before centrifugation.15 DNA extracted from each
sample was resuspended in 15 l of TE (Tris-EDTA, pH 7.5)
buffer. Quantification of extracted DNA was performed using
the NanoDrop spectrophotometer (NanoDrop Technologies,
Wilmington, DE).
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Whole Genome Amplification
Whole genome amplification was done with the Qiagen
REPLI-g Midi Kit (cat 150045, Qiagen, Hilden, Germany).
Briefly, 20 ng of extracted genomic DNA in a 5 l volume
was mixed with 5 l of denaturation buffer (D1) and incu-
bated for 3 minutes at room temperature. This was followed
by adding 10 l of neutralization buffer (N1). Thirty micro-
liters of the master mix (REPLI-g Midi Reaction Buffer 
REPLI-g Midi DNA Polymerase) was added to the denatured
DNA and incubated at 30°C for 16 hours to achieve maxi-
mum DNA yield (40 g). REPLI-g Midi DNA polymerase
was inactivated by heating at 65°C for 3 minutes. Amplified
DNA was stored at 20°C.
PCR and Purification of PCR Products
Exons 18–21 of EGFR, exons 4–9 of p53, exon 2 of
KRAS and exons 13–22 of CMET were amplified by poly-
merase chain reaction (PCR). Primer sequences (forward and
reverse, respectively) and PCR conditions are as follows:
EGFR-Exon18F: -CAAATGAGCTGGCAAGTGCCGTGTC-
EGFR-Exon18R: -GAGTTTCCCAAACACTCAGTGAAAC-
EGFR-Exon19F: -GCAATATCAGCCTTAGGTGCGGCTC-
EGFR-Exon19R: -CATAGAAAGTGAACATTTAGGAT-
GTG
EGFR-Exon20F: -CCATGAGTACGTATTTTGAAACTC-
EGFR-Exon20R: -CATATCCCCATGGCAAACTCTTGC-
EGFR-Exon21F: -CTAACGTTCGCCAGCCATAAGTCC-
EGFR-Exon21R: -GCTGCGAGCTCACCCAGAAT-
GTCTGG-
p53-Exon5–6F: -CTAGCTCGCTAGTGGGTTG-
p53-Exon5–6R: -AGGAGAAAGCCCCCCTACTG-
p53-Exon7F: -TGCTTGCCACAGGTCTCC-
p53-Exon7R: -AAGCTCCAGCTCCAGGTAGG -
p53-Exons8–9F: -TTCCTTACTGCCTCTTGCTT-
p53-Exons8–9F: -GAAAACGGCATTTTGAGTG-
KRAS-Exon2F: -TTCTTAAGCGTCGATGGAGG–
KRAS-Exon2R: -ACAGAGAGTGAACATCATGGAC-
CMET-Exon13F: -GGCAGTTATGCCATTTGTAGAAT-
CMET-Exon13R: -AGCGAACTAATTCACTGCCC-
CMET-Exon14F: -CCATGAGTTCTGGGCACTG-
CMET-Exon14R: -GCAGAGGTAAATACTTCCTTTAG-
GTTT-
CMET-Exon15F: -AGCATGGCTTTTTGCTATTGA-
CMET-Exon15R: -GCTCTGTCAGTTGCTTTCACC-
CMET-Exon16F: -CACACCTACGTACCTATAGTGG-
TATTG-
CMET-Exon16R: -TTTTCCACAAGGGGAAAGTG-
CMET-Exon17F: -AAACCCTCAGGACAAGATGC-
CMET-Exon17R: -AGGGATGGCTGGCTTACAG-
CMET-Exon18F: -AGGCTTGAGCCATTAAGACC-
CMET-Exon18R: -ATCCCCAGGGCTTACACATC-
CMET-Exon19F: -TGGCAATGTCAATGTCAAGC-
CMET-Exon19R: -TGAAGAAAACTGGAATTGGTG-
CMET-Exon20F: -TGTTGCCCAAAACAGAAACC-
CMET-Exon20R: -AAGGCAGGCATTTCTGTAAAAG-
CMET-Exon21F: -TCCTACAACCCGAATACTGC-
CMET-Exon21R: -CCCAGAAGGAGGCTGGTC-
CMET-Exon22F: -TGTCAAAGCAACAGTCCACAC-
CMET-Exon22R: -TGGGTGAATGACACCATCAG-
All PCR assays were carried out in a 20 l volume that
contained 30 ng of DNA, 1 unit of Platinum TaqDNA
polymerase (Invitrogen, CA) and 0.3 mM of dNTP (Bioline
Ltd, London, UK). Each PCR reaction volume was subjected
to 95°C for 5 minutes, then DNA was amplified for 35 cycles
at 95°C for 30 seconds, 56°C for 30 seconds, 72°C for 1
minute, with a final extension time of 10 minutes at 72°C.
QiaQuick PCR purification kits (Qiagen, Hilden, Germany)
were used.
DNA Sequencing
Purified PCR products were sequenced in forward and
reverse directions using the ABI PRISM BigDye Terminator
Cycle Sequencing Ready Reaction kit (Version 3) and ABI
PRISM 3730 Genetic Analyzer (Applied Biosystems, CA).
Chromatograms were analyzed by SeqScape V2.5 and man-
ual review.
Statistical Analysis
Survival distribution functions were estimated using
the Kaplan-Meier product limit method. Standard errors of
the Kaplan Meier estimates were computed by using Green-
wood’s formula. The effects of EGFR, KRAS, p53, and
CMET mutational status on the survival time of the patient
were studied via the Cox proportional hazards model. As
additional confounding variables such as the patient’s age and
sex were deemed likely to influence survival time, these
variables were taken into account when assessing the extent
of any exposure difference. We included these variables in
the Cox regression models. Likelihood ratio tests were used
to compare alternative models. Fisher’s exact test tests were
used to compare the EGFR mutation rates between genders,
adenocarcinoma and nonadenocarcinoma subtypes and smok-
ing versus nonsmoking status. Independent two-sample tests
for proportions were used to compare the mutation propor-
tions between the early-stage patients and the advanced-stage
patients.
Statistical analyses were performed in SAS software
(version 9.2, SAS institute, Cary, NC). Graphs were produced
in R system, available from Comprehensive R Archive Net-
work (http://www.CRAN.R-project.org).
RESULTS
Similar Sensitivity and Accuracy in Detecting
EGFR, p53, and KRAS Mutations in
WGA-Amplified Versus Unamplified Samples of
Surgically Resected Lung Tumors
Several commercially available WGA kits were ini-
tially assessed using genomic DNA extracted from cell lines,
which were either mutant or wildtype for particular genes
(data not shown). Through a series of mixing experiments,
where mutant and wildtype DNA were present in differing
quantities, we selected the WGA kit that was most sensitive
in subsequent mutation detection via direct sequencing. This
kit was used for all subsequent WGA-based analyses.
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We proceeded to assess the rate of fidelity of mutation
detection in WGA-amplified versus unamplified genomic
DNA from surgically resected lung tumor tissues. Figure 1
illustrates the comparison of DNA sequence chromatograms
of genomic DNA extracted from fresh frozen surgical lung
tissue resections, known to be wildtype or mutant for EGFR,
KRAS, and p53. For the lung samples that possessed muta-
tions, we compared the DNA sequence variation obtained
from unamplified and WGA-amplified genomic DNA. As
shown, the mutations were not lost after the WGA process.
The heterozygous EGFR exon 19 deletion (delE746-A750),
heterozygous KRAS exon 2 point mutation (G12C) and het-
erozygous p53 exon 5 deletion (delR158-Y163) present in
unamplified genomic DNA are similarly detected in WGA-
amplified genomic DNA, with similar peak-to-peak ratios.
Similar Sensitivity and Accuracy in Detecting
p53 Mutations in WGA-Amplified Versus
Unamplified Samples of Low-Volume Lung
Biopsies
We analyzed low-volume lung biopsies known to be
wildtype or mutant for p53 from our previous work.6 The
FIGURE 1. Detection of deoxyribonucleic acid (DNA) mutations in unamplified and whole genome amplification (WGA)-am-
plified genomic DNA (gDNA) extracted from surgically-resected lung tumors. Left column, Sequence chromatograms of wild-
type tumors using unamplified gDNA. Middle column, Sequence chromatograms of mutation-bearing tumors using unampli-
fied gDNA. Right column, Sequence chromatograms of mutation-bearing tumors, same as in the middle column, but using
WGA-amplified gDNA. Identity numbers of the mutation-bearing tumors are listed on the right. A, epidermal growth factor
receptor (EGFR) exon 19: the start of the heterozygous in-frame deletion (delE746-A750) is indicated by the arrows. B, Kras
exon 2: the heterozygous missense mutation (G12C) is indicated by the arrows. C, p53 exon 5: the start of the heterozygous
in-frame deletion (delR158-Y163) is indicated by the arrows.
FIGURE 2. Detection of deoxyribonucleic acid (DNA) mutations in unamplified and whole genome amplification (WGA)-am-
plified genomic DNA (gDNA) extracted from low-volume lung biopsies. Left column, Sequence chromatograms of wildtype
tumors using unamplified gDNA. Middle column, Sequence chromatograms of mutation-bearing tumors using unamplified
gDNA. Right column, Sequence chromatograms of mutation-bearing tumors, same as in the middle column, but using WGA-
amplified gDNA. Identity numbers of the mutation-bearing tumors are listed on the right. A, p53 exon 5: the heterozygous
missense mutation (R158L) is indicated by the arrows. B, p53 exon 7: the heterozygous missense mutation (Y236stop) is indi-
cated by the arrows.
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mutant samples were G40 and G3, the former being a fine-
needle aspirate, and the latter being a core biopsy. Owing to
the tissue acquisition technique, G40 is of lower tissue quan-
tity than G3. Extracted DNA leftover from our previous
analysis was used here. As shown in Figure 2, the mutations
were still present after the WGA process. The heterozygous
p53 exon 5 (R158L) and exon 7 (Y236stop) point mutations
are preserved in the WGA-amplified DNA, albeit of varying
peak-to-peak ratios, as compared with unamplified DNA.
Figure 2 shows 1:1 versus 1:3 mutant-to-wildtype allele
peak-to-peak ratios for unamplified and WGA-amplified G3
samples, respectively. Conversely, the peak-to-peak ratios are
2:5 and 4:5 for unamplified versus WGA-amplified G40
samples.
Characteristics of Patients and Tissue Samples
for Sequence Analysis from WGA-Amplified
Genomic DNA
A total of 96 ethnic Chinese patients were included in
this study. The low-volume lung biopsy study samples were
not microscopically examined, but their corresponding diag-
nostic biopsy reports showed that four were lung secondaries
(primary tumors were breast, colon, pancreas, and tonsil), one
was a malignant mesothelioma, one was a low-grade MALT
lymphoma, two were nonmalignant with inflammatory and/or
necrotic changes. The remaining 88 were biopsies of lung
primaries, and their corresponding diagnostic biopsy samples
were cytologically assessed as NSCLC. They were of ad-
vanced-stage disease. All samples were grouped according to
the acquisition technique, via (1) bronchoscopy, (2) percuta-
neous core biopsy, and (3) percutaneous fine needle aspira-
tion (Table 1).
The patient populations are demographically homoge-
neous across the three groups, dominated by males (72%) and
smokers (71%). The histologic subtype distribution reflects
the intrinsic clinical presentation and tissue acquisition tech-
nique used: adenocarcinomas and squamous cell carcinomas
are usually situated peripherally and centrally, respectively,
and therefore tend to be biopsied via the percutaneous and
endoscopic routes, respectively. The larger amount of tissue
obtained through bronchoscopy and core biopsy, as compared
with fine needle biopsy, likely accounts for the a lower
proportion of samples that cannot be confidently subtyped
(NSCLC unspecified: bronchoscopy 15% and core biopsy
24% versus fine needle aspirate 38%).
Detection of EGFR, KRAS, p53, and CMET
Mutations in 88 Samples of Advanced Stage
NSCLC
Table 2 shows the numbers, types and distribution of
mutations detected in 43 of 88 samples of advanced stage
NSCLC using direct sequencing of WGA-amplified genomic
DNA from low-volume lung biopsies. Mutations were iden-
tified regardless of the mode of tissue acquisition: 21 of 46
core biopsies (46%), 3 of 13 bronchoscopic biopsies (23%),
and 19 of 29 fine needle aspirates (66%).
The proportion of samples bearing EGFR, p53, KRAS,
and CMET sequence variations were 21 of 88 (24%), 24 of 88
(27%), 5 of 88 (6%), and 1 of 88 (1%), respectively. The two
commonest EGFR mutations, exon 19 deletion and exon 21
L858R missense mutation, were present in 33% (n  7) and
48% (n  10), respectively, of samples with EGFR muta-
tions. There were three samples that had double EGFR
mutations. As previously described elsewhere, EGFR and
KRAS mutations were mutually exclusive. However, there
were 7 samples with dual EGFR p53 mutations, and 1 with
KRAS  p53 mutations.
We observed the well-known correlation of EGFR
mutations with clinical phenotypes of female gender (p 
0.0014), adenocarcinoma subtype (p  0.00003) and non-
smoking history (p  0.0002), using the Fisher’s exact test.
Assessing Association of Mutational Status and
Survival
Figure 3A shows a Kaplan Meier probability plot of
overall survival in the 88 NSCLC patients whose tumors were
subjected to mutational analysis as described above. At last
observation, 56 were alive. The censoring proportion was
considerably high (approximately 64%).
To determine the impact on survival by mutational
status, we considered the Cox proportional hazards regression
model. Other variables, e.g., age, gender, were also taken into
account. The results are shown in Table 3. Overall, there was
a survival advantage for patients who received systemic
treatment (hazard ratio: 0.312, p  0.03); they comprised
56% (49 of 88) of the group. There were 10 patients treated
with TKI, of which 7 were EGFR mutation positive. Treat-
ment decisions were made independent of knowledge of
TABLE 1. Characteristics of Patients and Lung Biopsies
Bronchoscopic
Biopsy
Needle
Aspirate
Core
Biopsy Overall
No. of patients 15 30 51 96
Age, yr
Median 69 67 71 69
Range 48–73 44–89 29–92 29–92
Gender
Male 12 (80%) 20 (67%) 40 (78%) 72 (75%)
Female 3 (20%) 10 (33%) 11 (22%) 24 (25%)
Smoking status
Smokers and
ex-smokers
11 (73%) 21 (70%) 39 (76%) 71 (74%)
Never smokers 4 (27%) 9 (30%) 12 (24%) 25 (26%)
Histology
NSCLC 13 29 46 88
Adenocarcinoma 1 (8%) 15 (52%) 26 (57%) 42 (48%)
Squamous cell
carcinoma
9 (69%) 2 (7%) 8 (17%) 19 (22%)
Adenosquamous 0 1 (3%) 0 1 (1%)
Large cell
carcinoma
1 (8%) 0 1 (2%) 2 (2%)
Unspecified 2 (15%) 11 (38%) 11 (24%) 24 (27%)
Malignant (non-
NSCLC)
2 1 3 6
Nonmalignant 0 0 2 2
NSCLC, non-small cell lung cancer.
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TABLE 2. Clinicopathological Factors and Mutations Detected in Advanced-Stage NSCLC Tumors by Direct Sequencing of
WGA-Amplified Genomic DNA from Low-Volume Lung Biopsies
Sample
Identity Gender
Age,
yr Cytology
Smoking
Status EGFR p53 Kras c-met Biopsy Procedure
G73 F 58 Adenosquamous
carcinoma
NS Exon 18: G719A (GC) Exon
20: R776H (GA)
Exon 8: C275F Needle aspirate
V153 M 67 Adenocarcinoma S Exon 18: E709A (AC) Exon
21: L858R (TG)
Exon 5: V157F Core biopsy
V83 M 79 Adenocarcinoma S Exon 19: 9bp del (L747-E749)
Exon 19: A750P (GC)
Core biopsy
G75 F 44 Adenocarcinoma NS Exon 19: 15bp del (E746-A750) Needle aspirate
V31 F 53 Adenocarcinoma NS Exon 19: 15bp del (E746-A750) Exon 7: R248W Core biopsy
V71 F 70 Adenocarcinoma NS Exon 19: 15bp del (E746-A750) Core biopsy
V139 M 76 Adenocarcinoma NS Exon 19: 15bp del (E746-A750) Core biopsy
G66 F 60 Adenocarcinoma NS Exon 19: 15bp del (L747-T751) Exon 5: V172F Needle aspirate
H13 F 81 Adenocarcinoma NS Exon 19: 15bp del (K745-E749) Needle aspirate
G45 M 61 NSCLC unspecified S Exon 20: M766T (TC) Needle aspirate
V162 F 63 Adenocarcinoma NS Exon 20: 6bp ins P774-H775 Core biopsy
V17 M 50 Adenocarcinoma NS Exon 21: L858R (TG) Exon 8: R273C Needle aspirate
P92 M 52 Adenocarcinoma S Exon 21: L858R (TG) Exon 5: 4 bp ins
W146
Needle aspirate
V43 82 M Adenocarcinoma S Exon 21: L858R (TG) Core biopsy
V104 63 F Adenocarcinoma NS Exon 21: L858R (TG) Core biopsy
V141 76 F Adenocarcinoma NS Exon 21: L858R (TG) Core biopsy
V180 68 M Adenocarcinoma S Exon 21: L858R (TG) Core biopsy
B127 62 M Adenocarcinoma S Exon 21: L858R (TG) Exon 7: N239S Forceps
V80 79 F Adenocarcinoma NS Exon 21: L858R (TG) Core biopsy
V169 42 M Squamous cell
carcinoma
S Exon 21: L858R (TG) Core biopsy
V197 69 M Adenocarcinoma S Exon 21: L858R (TG) Core biopsy
B107 70 M Squamous cell
carcinoma
S Exon 8: 1 bp del
E297
Forceps
G72 82 M Squamous cell
carcinoma
S Exon 5: V173M Needle aspirate
H4 59 M NSCLC unspecified S Intron 6: 5 bp del Needle aspirate
P78 72 M Adenocarcinoma S Exon 6: 18 bp del
E198 Exon 6:
E204A
Needle aspirate
P81 67 M Squamous cell
carcinoma
S Exon 6: E224D Needle aspirate
T21 83 M NSCLC unspecified S Exon 5: 4 bp del
S149
Needle aspirate
V20 78 M Adenocarcinoma S Exon 7: G244C Needle aspirate
V55 87 M Adenocarcinoma S Exon 8: R273H Needle aspirate
V56 59 M NSCLC unspecified S Exon 5: 1 bp ins
P152
Core biopsy
V107 65 M Adenocarcinoma S Exon 6: Y205F Core biopsy
V112 76 M Squamous cell
carcinoma
S Exon 7: E258D Core biopsy
V113 76 M Adenocarcinoma S Exon 8: R273L Core biopsy
V121 47 M Adenocarcinoma S Exon 7: G245V Needle aspirate
V144 73 M Adenocarcinoma S Exon 5: V173M
Exon 6: V216L
Core biopsy
V152 72 M Large cell carcinoma S Exon 5: 1 bp del
P152
Core biopsy
V154 49 M NSCLC unspecified S Exon 7: R248W Needle aspirate
V159 76 F NSCLC unspecified S Exon 5: R158L Exon 2: G12C (GT) Needle aspirate
B151 63 M NSCLC S Exon 2: G12D (GC) Forceps
P70 63 F Adenocarcinoma S Exon 2: G12C (GT) Needle aspirate
V177 92 F Adenocarcinoma S Exon 2: G12C (GT) Core biopsy
G80 78 F NSCLC unspecified S Exon 2: G12C (GT) Needle aspirate
V138 70 M NSCLC unspecified S 17 bp del splice
region
NSCLC, non-small cell lung cancer; M, male; F, female; NS, neversmokers; S, smokers; EGFR, epidermal growth factor receptor; WGA, whole genome amplification; DNA,
deoxyribonucleic acid.
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TABLE 3. Association of KRAS, CMET, p53, and EGFR
Mutations with Overall Survival Using Cox proportional
Hazards Regression Model
Coefficient
(Standard Error)
Hazard
Ratio p
KRAS 1.618 (0.619) 5.05 0.009
CMET 3.163 (1.120) 23.65 0.0048
p53 0.250 (0.415) 0.778 0.55
EGFR 0.5379 (0.5881) 0.584 0.360
Age  EGFR 0.0826 (0.0389) 0.921 0.034
EGFR, epidermal growth factor receptor.
TABLE 4. Comparing EGFR, KRAS, and p53 Mutation
Frequencies Between Advanced-Stage and Early-Stage
NSCLC
Advanced Stage NSCLC
(n  88)
Early Stage NSCLC
(n  133) p
EGFR 24% 20% 0.48
p53 27% 29% 0.75
Kras 6% 10% 0.27
NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor.
FIGURE 3. A, Overall survival of 88 non-small cell lung cancer (NSCLC) patients (survival time in days). The dotted lines indi-
cate 95% confidence intervals. B, Survival curves of patients with and without KRAS mutations (survival time in days). C, Sur-
vival curves of patients with and without epidermal growth factor receptor (EGFR) mutations (survival time in days).
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mutational status. Whether patients received systemic treat-
ment or not was also controlled for in the subsequent correl-
ative studies on survival and gene mutations.
It seems that KRAS and CMET mutations are indepen-
dently associated with decreased survival (Figure 3B, similar
curve for CMET). Mutations in EGFR had no significant
impact on survival, nor did mutations in p53 (Figure 3C,
similar curve for p53). Disruptive versus nondisruptive p53
mutations also did not significantly affect survival (see Dis-
cussion). However, there was significant interaction between
age and EGFR mutations, i.e., as age increases by 1 year, the
hazard decreases to 92.1% of the original hazard. Hence,
there is a protective effect due to EGFR mutations, which
becomes stronger as the age at diagnosis is greater.
We also considered the effect on survival of combined
mutations, i.e., EGFR  p53, KRAS  p53, but this was
nonsignificant, using the likelihood ratios test.
Comparison of Mutation Frequencies Between
Advanced- and Early-Stage NSCLC
Table 4 shows the comparison in mutation frequencies
between 133 surgically-resected early-stage disease, and this
set of 88 patients with advanced-stage disease. There is no
significant difference between both groups for mutations in
EGFR (p  0.48), p53 (p  0.75) and KRAS (p  0.27), by
using independent two-sample tests of proportions. The his-
tologic distribution of the surgically-resected samples is 55%
(73 of 133) adenocarcinoma and 45% (60 of 133) nonadeno-
carcinoma. All 27 of the EGFR mutations were found in the
adenocarcinoma specimens. Of the 13 KRAS mutations, 12
were detected in adenocarcinomas and 1 in squamous cell
carcinoma. The p53 mutations were more evenly distributed,
where 23 of 38 (61%) were found in adenocarcinomas. EGFR
and KRAS mutations were mutually exclusive. The squamous
cell carcinoma specimen that possessed the KRAS mutation
also bore a p53 mutation. All the other double mutations
occurred in adenocarcinomas, 12 with EGFR  p53 muta-
tions, and 3 with KRAS  p53 mutations.
DISCUSSION
The scarcity of genomic DNA from clinical samples
has been a limiting factor in the comprehensive molecular
analysis of advanced-stage NSCLC. Many investigations,
including array-based technology for genome-wide associa-
tion studies, require DNA of sufficiently high biologic integ-
rity, quality and quantity. The development of whole genome
amplification (WGA) has allowed for high-fidelity in vitro
reproduction of quality template DNA.11–14 Many commer-
cially available WGA kits use the multiple displacement
amplification technology, which carries out isothermal ge-
nome amplification with a uniquely processive DNA poly-
merase capable of replicating up to 100 kb without dissoci-
ating from the genomic DNA template. The DNA polymerase
has a 3 to 5 exonuclease proofreading activity to maintain
high fidelity during replication and is used in the presence
of exonuclease-resistant primers to achieve high yields of
DNA product (40 g). The average product length is
typically greater than 10 kb, with a range between 2 kb and
100 kb. There is resultant highly uniform amplification
across the entire genome, with negligible sequence bias.
We used the Qiagen REPLI-g whole genome amplification
kit in this study.
From the technical perspective, demonstrating the fea-
sibility of WGA in multiple mutational analysis in low-
volume lung biopsies opens the door to further array-based
analysis that require a greater amount of starting DNA ma-
terial, e.g., DNA copy number variations, methylation. In
fact, WGA-amplified genomic DNA has been subjected to
array-based comparative genomic hybridization.15 With
WGA, early- and advanced-stage disease can be meaning-
fully compared on a full complement of standardized analysis
platforms.
We had previously attempted to address the molecular
differences between early- and advanced-stage NSCLC by
first exploring the approaches towards maximizing the
amount of molecular information obtainable from advanced-
stage disease with current clinical procedures. The main
drawback of analyzing low-volume lung biopsies is the pau-
city of starting DNA and RNA material. We had assessed the
feasibility of RNA amplification of low-volume lung biopsy
tissues separately acquired during the diagnostic procedure,
from which we obtained RNA expression profiles.5 The
results supported the feasibility of the methods used. We also
assessed the typical amounts of genomic DNA extractable
from low-volume lung biopsies similarly acquired, and the
limits of DNA mutation data (via direct sequencing) that
could be eked out from them.6 Here, we have shown that
sequencing of WGA-amplified genomic DNA can reproduce
mutations detected from unamplified genomic DNA. This
concordance in sequence data was not extended beyond one
mutation in the two low-volume samples analyzed (Results
subsection two) because of the limited amount of extractable
DNA per sample.
The clinical premise of this work was to assess the
feasibility of WGA in analyzing a panel of mutations in
advanced-stage NSCLC, which may in turn guide treatment
decisions in future on a more individualized basis. Although
only a few genes were assessed in this study, the number of
genes that could be analyzed is potentially limitless, given the
micrograms of amplified genomic DNA obtained. Although
we are unlikely to ever be able to comprehensively test the
fidelity of WGA-amplified genomic DNA, as we do not
surgically resect primary tumors of advanced-stage disease
for comparison’s sake, the results presented here are encour-
aging. This technique allows the future evaluation of more
gene mutations and their impact on prognosis and treatment
decisions. If new treatments are developed that are targeted
towards specific gene mutations, then this analysis platform is
relevant, especially if treatment is considered in a combina-
torial fashion. If the prognostic value of a set of mutations is
validated, this may guide decisions on treatment initiation in
patients with borderline performance status.
In this study, the statistically calculated deleterious
prognostic influence of KRAS and CMET mutations is tem-
pered by the small numbers of these mutations, hence diluting
their possible clinical significance. Nonetheless, the de-
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creased survival associated with KRAS mutations in our study
is partially consistent with other published work in both the
early- and advanced-stage setting. In the TRIBUTE trial
looking at advanced NSCLC treated with chemotherapy ver-
sus chemotherapy plus erlotinib, a retrospective subgroup
analysis found that KRAS mutations did not have prognostic
significance.4 For resected NSCLC, a worse prognosis asso-
ciated with KRAS mutation-containing lung tumors was ini-
tially described by Rodenhuis et al.16 A subsequent meta-
analysis17 concluded that patients with KRAS mutations had a
significantly poorer prognosis compared with KRAS wild-
type, with a combined hazard ratio of 1.35 (95% confidence
interval 1.16–1.56). However, analysis of KRAS mutational
status in the JBR10 trial patients where adjuvant chemother-
apy (cisplatin and vinorelbine) was compared with observa-
tion did not demonstrate prognostic nor predictive value.18,19
Tumors bearing KRAS mutations also seem to be resistant to
EGFR TKI therapy.20–22 The TRIBUTE patients with KRAS
mutations who received erlotinib with chemotherapy had
poorer clinical outcomes than those treated with chemother-
apy alone.4 At present, there is no effective therapy targeting
KRAS-bearing tumors, although an immunotherapeutic ap-
proach seems interesting.23
The MET receptor tyrosine kinase and its cognate
ligand hepatocyte growth factor (HGF) promote cell prolif-
eration, invasion, motility and angiogenesis in in vitro stud-
ies.24–31 The clinical significance of the HGF/MET oncogenic
signaling was initially described by Siegfried et al.32, where
high levels of HGF indicated worse clinical outcomes in
early-stage NSCLC patients. In cell line studies, mutations of
CMET have been identified that lead to its increased expres-
sion.33 In our study, although CMET mutations did not occur
frequently, it was significantly correlated with decreased
survival. Drugs targeting MET have been developed that
induce response in tumor xenograft models,34 as well as being
synergistic with other targeted agents,35 further enhancing its
potential relevance in clinical therapeutics.
The prognostic significance of p53 mutations and ex-
pression in NSCLC had been examined previously, with a
few meta-analyses inclining towards abnormal p53 status
being associated with poorer prognosis.36–40 A recent analy-
sis of p53 mutational status in resected NSCLC in the JBR10
trial did not support its prognostic value.19 Our results also do
not support the role of p53 as a prognostic indicator in
advanced-stage NSCLC. We also did not discern any survival
difference between disruptive versus nondisruptive p53 mu-
tations, which did have a significant impact on prognosis in
head and neck cancer.41
The lack of significant association between EGFR mu-
tations and survival in our study was interesting. Several
prospective trials have shown that tumors with EGFR muta-
tions (most commonly being the exon 19 deletion and exon
21 L858R mutation) have a response rate of 75% when
treated with EGFR TKI such as gefitinib and erlotinib.10 In
the subgroup analysis of the TRIBUTE trial, patients with
EGFR mutations had significantly better clinical outcomes
than EGFR wildtype, whether or not they received erlotinib.
However, other studies of early-stage disease have not found
significant differences in overall survival between patients
with EGFR mutations and EGFR wildtype.42,43 The interim
results of the INTEREST trial looking at second-line treat-
ment with gefitinib or docetaxel in advanced-stage NSCLC
were presented at the World Congress on Lung Cancer in
September 2007.44 It seemed that there was no correlation
between survival and EGFR abnormal status, i.e., mutations,
gene copy number and expression, which was consistent with
our results. The interaction between age of diagnosis and
EGFR mutation was thought-provoking. We can only sur-
mise that other larger-scale genomic changes associated with
increasing age and cancer, e.g., global hypomethylation and
the ‘spreading’ phenomenon45,46 affecting gene expression,
may interact with EGFR mutation-related molecular signals,
giving rise to a net effect of survival benefit.
The comparison of mutation frequencies of EGFR,
KRAS, and p53 between early- and advanced-stage disease
have not yielded significant differences in this study. This
suggests the presence of these gene mutations in the early
stages of carcinogenesis. The evolution of disease from
early-stage to advanced-stage would probably be attributable
to the acquisition of mutations in other genes, emphasizing
the need to interrogate other genes responsible for increased
invasive cell behavior with high metastatic potential. The
rapid advancement of genome sequencing technology en-
hances greater efficiency in this endeavor, and WGA-ampli-
fied genomic DNA enables a comprehensive evaluation of
low-volume lung biopsies from advanced-stage NSCLC. As
mentioned earlier, WGA-amplified genomic DNA allows for
concurrent analysis of advanced-stage NSCLC on multiple
platforms, facilitating comparisons with similar analyses in
resected early-stage NSCLC, thereby elucidating and refining
the identification of genes implicated in disease progression
from early- to late-stage.
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